AF
JAZZ icon

Affiance Financial’s Jazz Pharmaceuticals JAZZ Stock Holding History

Affiance Financial’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-108
Closed -$17.2K – 269
2022
Q4 		$17.2K Buy
+108
New +$15.8K 0.01% 253

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Affiance Financial's JAZZ Position: Q1 2023 in Review

Affiance Financial sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 108 shares — an estimated $17.2K sold.

Affiance Financial first reported a position in JAZZ in Q4 2022 and held it in 1 quarter. The position peaked at $17.2K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

  • Affiance Financial reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Affiance Financial sold 108 Jazz Pharmaceuticals shares in Q1 2023, an estimated $17.2K.
  • Affiance Financial first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Affiance Financial's Jazz Pharmaceuticals position peaked at $17.2K in Q4 2022.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Affiance Financial's 13F filing for Q1 2023, filed 18 Apr 2023.